See more : Acciona, S.A. (ACXIF) Income Statement Analysis – Financial Results
Complete financial analysis of Perspective Therapeutics, Inc. (CATX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perspective Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- TMP Steel Corporation (6248.TWO) Income Statement Analysis – Financial Results
- Kapston Services Limited (KAPSTON.NS) Income Statement Analysis – Financial Results
- Gruma, S.A.B. de C.V. (GPAGF) Income Statement Analysis – Financial Results
- Omai Gold Mines Corp. (OMGGF) Income Statement Analysis – Financial Results
- Namsun Aluminum Co., Ltd. (008350.KS) Income Statement Analysis – Financial Results
Perspective Therapeutics, Inc. (CATX)
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.43M | 7.10M | 10.80M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M | 4.22M | 4.53M | 5.07M | 5.24M | 5.29M | 5.42M | 7.16M | 5.74M | 1.99M | 201.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.85M | 8.26M | 7.82M | 6.79M |
| Cost of Revenue | 0.00 | 5.47M | 6.18M | 4.93M | 4.56M | 4.27M | 4.08M | 3.92M | 4.64M | 4.44M | 4.42M | 4.38M | 4.37M | 4.08M | 4.56M | 5.77M | 7.31M | 5.79M | 3.82M | 1.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.68M | 7.46M | 6.99M | 6.42M |
| Gross Profit | 1.43M | 1.63M | 4.62M | 5.12M | 5.12M | 3.05M | 1.84M | 838.00K | 129.15K | 167.39K | -196.47K | 150.18K | 703.20K | 1.16M | 725.80K | -353.33K | -151.43K | -54.60K | -1.82M | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 795.61K | 822.28K | 367.89K |
| Gross Profit Ratio | 100.00% | 23.00% | 42.76% | 50.94% | 52.93% | 41.66% | 31.10% | 17.60% | 2.71% | 3.63% | -4.66% | 3.32% | 13.87% | 22.09% | 13.73% | -6.52% | -2.12% | -0.95% | -91.30% | -630.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.84% | 9.63% | 10.52% | 5.42% |
| Research & Development | 21.31M | 2.60M | 2.58M | 1.43M | 1.13M | 1.47M | 1.75M | 965.00K | 528.05K | 614.77K | 668.80K | 627.11K | 730.58K | 465.33K | 340.96K | 958.67K | 1.36M | 1.35M | 450.43K | 137.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.97M | 10.87M | 6.62M | 4.69M | 4.57M | 4.17M | 4.17M | 3.92M | 3.79M | 2.40M | 2.49M | 2.29M | 2.36M | 2.42M | 2.44M | 2.79M | 7.29M | 8.30M | 4.92M | 0.00 | 30.00K | 9.10K | 19.02K | 7.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 97.00K | 3.23M | 2.80M | 2.44M | 2.98M | 2.68M | 2.66M | 2.31M | 1.35M | 1.49M | 1.23M | 1.30M | 1.22M | 1.23M | 1.95M | 2.37M | 0.00 | 0.00 | 0.00 | 0.00 | -20.91K | 9.93K | -11.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.06M | 14.21M | 9.43M | 7.13M | 7.55M | 6.85M | 6.83M | 6.23M | 5.14M | 3.89M | 3.72M | 3.59M | 3.57M | 3.66M | 4.39M | 5.16M | 7.29M | 8.30M | 4.92M | 2.57M | 9.10K | 19.02K | 7.58K | 7.58K | 0.00 | 15.53K | 221.88K | 1.11M | 2.59M | 1.24M | 1.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -73.00K | 2.00K | 0.00 | -48.00K | -456.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.99K | 15.57K | 0.00 | 207.30K | 942.00 | 317.97K | 316.74K | 406.92K |
| Operating Expenses | 42.38M | 17.43M | 12.01M | 8.56M | 8.60M | 8.33M | 8.57M | 7.15M | 5.21M | 4.50M | 4.39M | 4.22M | 4.30M | 4.12M | 4.73M | 6.12M | 8.65M | 9.65M | 5.37M | 2.71M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 1.43M | 2.91M | 1.65M | 1.54M |
| Cost & Expenses | 42.38M | 22.90M | 18.19M | 13.49M | 13.16M | 12.59M | 12.65M | 11.07M | 9.85M | 8.94M | 8.81M | 8.59M | 8.67M | 8.20M | 9.29M | 11.89M | 15.96M | 15.44M | 9.19M | -4.18M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 8.11M | 10.37M | 8.64M | 7.96M |
| Interest Income | 934.00K | 1.12M | 119.00K | 59.00K | 30.00K | 108.00K | 29.00K | 118.00K | 218.15K | 282.75K | 12.11K | 664.00 | 747.00 | 3.38K | 11.43K | 111.05K | 0.00 | 0.00 | 0.00 | 2.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 84.00K | 0.00 | 119.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 950.00 | 2.21K | 883.00 | 7.00 | 61.68K | 216.61K | 36.39K | 75.31K | 274.00K | 0.00 | 1.02M | 167.49K | 0.00 | 2.10K | 41.01K | 51.50K | 0.00 | 0.00 | -12.44K | 0.00 | 163.27K | 66.96K | 108.63K |
| Depreciation & Amortization | 981.00K | 344.00K | 248.00K | 9.00K | 147.00K | -24.00K | 80.00K | 68.00K | 470.85K | 576.38K | 685.40K | 739.15K | 847.12K | 888.57K | 996.88K | 1.21M | 1.06M | 715.25K | 655.33K | 143.04K | 0.00 | 84.85K | -41.01K | -51.50K | 250.68K | -51.50K | 942.00 | 317.97K | 316.74K | 407.42K | 308.83K |
| EBITDA | -39.96M | -14.84M | -7.39M | -3.43M | -3.48M | -5.30M | -6.70M | -6.19M | -4.39M | -4.05M | -3.89M | -3.33M | -2.92M | -2.07M | -3.01M | -5.54M | -7.47M | -8.98M | -6.15M | -3.96M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -234.32K | 13.87K | -2.69M | -436.43K | -1.78M |
| EBITDA Ratio | -2,786.61% | -208.87% | -68.47% | -34.10% | -35.91% | -72.49% | -113.12% | -129.99% | -92.11% | -87.99% | -92.22% | -73.53% | -57.60% | -39.53% | -56.98% | -102.21% | -104.32% | -156.58% | -308.60% | -1,962.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | -32.56% | -5.58% | -26.22% |
| Operating Income | -40.94M | -15.18M | -7.39M | -3.44M | -3.48M | -5.28M | -6.73M | -6.31M | -5.08M | -4.34M | -4.59M | -4.07M | -3.60M | -2.96M | -4.01M | -6.47M | -8.80M | -9.70M | -7.20M | -3.98M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -222.83K | -260.71K | -2.11M | -827.94K | -1.17M |
| Operating Income Ratio | -2,855.02% | -213.71% | -68.47% | -34.19% | -35.91% | -72.16% | -113.61% | -132.47% | -106.56% | -94.13% | -108.75% | -89.88% | -70.95% | -56.56% | -75.84% | -119.43% | -122.97% | -169.04% | -360.79% | -1,974.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.32% | -25.55% | -10.59% | -17.21% |
| Total Other Income/Expenses | 835.00K | 512.00K | 119.00K | 50.00K | 30.00K | 134.00K | 29.00K | 27.00K | 154.00K | 374.61K | -1.38M | 210.00K | 170.00K | 334.00K | 0.00 | 274.00K | -274.00K | 0.00 | -385.51K | -285.99K | -2.10K | -2.10K | -41.01K | -51.50K | 0.00 | 0.00 | 12.44K | 43.40K | 895.74K | 15.91K | 920.60K |
| Income Before Tax | -40.11M | -14.67M | -7.27M | -3.39M | -3.45M | -5.14M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.43M | -2.84M | 0.00 | -6.20M | -9.08M | 0.00 | -8.22M | -4.27M | -11.20K | -60.03K | -59.08K | -59.08K | 0.00 | 0.00 | -3.09K | -423.98K | -2.15M | -936.57K | -435.09K |
| Income Before Tax Ratio | -2,796.79% | -206.50% | -67.36% | -33.69% | -35.60% | -70.33% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -67.60% | -54.25% | 0.00% | -114.37% | -126.79% | 0.00% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.40% | -26.03% | -11.98% | -6.41% |
| Income Tax Expense | -2.65M | 0.00 | -119.00K | -199.00K | -177.00K | -294.00K | -29.00K | -145.00K | -371.20K | -655.14K | 1.37M | -210.66K | -109.07K | -120.78K | 24.96K | -309.74K | -245.21K | -94.68K | 1.02M | 0.00 | -86.96K | -84.85K | 41.01K | 51.50K | -250.68K | 51.50K | -942.00 | 2.10K | 2.00K | 2.60K | 2.50K |
| Net Income | -46.51M | -14.67M | -7.15M | -3.19M | -3.27M | -4.85M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.49M | -2.84M | -4.03M | -6.16M | -8.56M | -9.61M | -8.22M | -4.27M | 75.76K | -60.03K | -59.08K | 235.11K | -65.65K | 1.82M | -139.55K | -426.08K | -2.15M | -939.17K | -437.59K |
| Net Income Ratio | -3,243.24% | -206.50% | -66.26% | -31.71% | -33.77% | -66.31% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -68.80% | -54.25% | -76.31% | -113.71% | -119.54% | -167.39% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.43% | -26.06% | -12.01% | -6.45% |
| EPS | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| EPS Diluted | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| Weighted Avg Shares Out | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.01M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
| Weighted Avg Shares Out (Dil) | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.02M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and...
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announces the selection of investigational product [212Pb]VMT‐α‐NET for the treatment of...
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for...
Perspective Therapeutics Announces $87.4 Million Private Placement
SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement...
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
Perspective Therapeutics (CATX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) -- -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has executed an exclusive license...
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the closing of its previously announced underwritten...
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten public offering...
Perspective Therapeutics Announces Proposed Public Offering
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has commenced an underwritten public...
Source: https://incomestatements.info
Category: Stock Reports